Income Statement
CARTESIAN THERAPEUTICS, INC.
RNAC
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
2.80 | 38.91 | 26.00 | 110.78 | 85.08 | 16.60 | 6.68 | 0.90 | 0.21 | 8.08 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
2.80 | 38.91 | 26.00 | 110.78 | 85.08 | 16.60 | 6.68 | 0.90 | 0.21 | 8.08 |
|
Operating Expenses
|
146.20 | 82.81 | 112.42 | 96.24 | 89.67 | 73.42 | 59.13 | 65.93 | 63.99 | 42.75 |
|
Research & Development
|
58.03 | 45.11 | 71.84 | 72.38 | 68.74 | 54.51 | 42.74 | 47.69 | 45.17 | 29.70 |
|
Selling, General & Administrative
|
31.47 | 30.13 | 40.58 | 23.86 | 20.94 | 18.91 | 16.39 | 18.24 | 18.83 | 13.05 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-143.41 | -43.90 | -86.42 | 14.54 | -4.60 | -56.82 | -52.46 | -65.02 | -63.78 | -34.67 |
|
Non-Operating Income
|
3.91 | 33.24 | 152.29 | -20.23 | 5.12 | - | - | - | - | - |
|
Interest Income
|
6.58 | 7.39 | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | 0.00 | 2.83 | 3.03 | 2.84 | 1.60 | 1.52 | 1.49 | 1.21 | 1.25 |
|
Other Non-Op Income / Expense
|
-2.01 | 0.61 | 0.69 | 0.33 | 0.02 | 0.09 | -1.31 | 0.01 | -0.15 | 0.00 |
|
Income Before Tax
|
-139.50 | -77.14 | -238.71 | 34.77 | -9.72 | - | - | - | - | - |
|
Income Tax Expense
|
-9.19 | 0.29 | -19.00 | -0.61 | 15.97 | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-130.30 | -77.42 | -219.71 | 35.38 | -25.69 | -68.88 | -55.35 | -65.34 | -65.32 | -36.21 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-143.41 | -43.90 | -86.42 | 14.54 | -4.60 | -56.82 | -52.46 | -65.02 | -63.78 | -34.67 |
|
Earnings Per Share (Basic)
|
-5.02 | -4.48 | -1.66 | 0.24 | -0.22 | - | - | - | - | - |
|
Diluted EPS
|
-5.02 | -4.49 | -1.66 | 0.10 | -0.22 | - | - | - | - | - |
|
Weighted Average Shares
|
25.97 | 17.28 | 155.11 | 144.76 | 114.33 | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
25.97 | 17.36 | 155.11 | 145.87 | 114.33 | - | - | - | - | - |
|
Comprehensive Income
|
-130.26 | -77.45 | -219.75 | 35.39 | -25.69 | -68.92 | -55.32 | -65.47 | -65.22 | -35.74 |